Back to top

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

Read MoreHide Full Article

Investors focused on the Medical space have likely heard of Amedisys (AMED - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Amedisys is one of 842 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AMED is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past three months, the Zacks Consensus Estimate for AMED's full-year earnings has moved 4.62% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

Our latest available data shows that AMED has returned about 2.90% since the start of the calendar year. In comparison, Medical companies have returned an average of 2.25%. This shows that Amedisys is outperforming its peers so far this year.

Looking more specifically, AMED belongs to the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and currently sits at #64 in the Zacks Industry Rank. This group has gained an average of 3.42% so far this year, so AMED is slightly underperforming its industry in this area.

AMED will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Amedisys, Inc. (AMED) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in